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Hammett TM. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med. 2003; 138:235-236 .
SUMMARY
Allen et al. described a retrospective observational study of 93 inmates with chronic hepatitis C infection; 90 underwent therapy with a combination of α-interferon and ribavirin. Response rates were similar to previously published rates achieved in nonincarcerated populations, with 60% achieving viral clearance after 6 months of therapy. A history of substance abuse was noted in 99%, with 76% injection drug users. Genotype 1 was the most common; 44% had a history of depression, and 4% had a history of a suicide attempt. The authors concluded that the incarcerated population, which is disproportionately affected by addiction and psychiatric illness, can be effectively treated for hepatitis C virus infection with interferon and ribavirin. They suggested that the correctional setting may provide an opportunity to safely treat patients with the challenging comorbid conditions of addiction and mental illness.
The accompanying editorial by Hammett pointed out the high prevalence (72%-86%) of hepatitis C virus infection in injection drug users and the disproportionately increased burden among African Americans. Hammett pointed out that relatively few correctional systems have systematic programs for diagnosis, treatment, and prevention of hepatitis C virus infection and called for a comprehensive approach to hepatitis C virus, including inmate and staff education, screening, diagnosis, and capitalization on the opportunity to help reduce hepatitis C virus transmission.
COMMENTARY
An estimated 29%-43% of all people infected with hepatitis C virus in the United States are released from incarceration each year. Death from end-stage liver disease related to chronic hepatitis C is a leading cause of mortality in some correctional facilities. Clearly, the period of incarceration is an important time to address hepatitis C virus.
Allen's article was the first description of hepatitis C treatment in the correctional setting. The regimen involved the use of the nonpegylated version of interferon, which is no longer the standard of care. Nevertheless, despite the significant comorbid conditions, the outcomes were comparable to those seen in populations without significant psychiatric or addiction comorbidity. Correctional systems, in fact, may be the ideal setting to provide comprehensive hepatitis C treatment to this population. As treatment for hepatitis C improves (it is hoped it will be less toxic, more effective, and possibly less expensive), the opportunities to address hepatitis C in this population will only increase.
HIV/AIDS Reviews
Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003; 348:701-710 .
SUMMARY
This was a large retrospective study of the risk of cardiovascular and cerebrovascular disease among almost 37,000 patients who received care for human immunodeficiency virus (HIV) infection at US Veterans Affairs (VA) facilities between 1993 and 2001. The source of the data was a central database developed from master databases of records from all VA facilities that included medications dispensed and admissions and discharge diagnoses. Data were augmented by information from VA death benefit claims, Social Security records, and the National Death Index. The records were comprehensive and relatively complete because VA services are comprehensive and usually free, primary diagnosis were available for more than 96% of admissions, and less than 5% of deaths were in non-VA facilities.
Five outcomes were reported: admission for any cardiovascular disease, admission for any cardiovascular disease or cerebrovascular disease, admission for or death from cardiovascular disease or cerebrovascular disease, death from any cause, and admission for any cardiovascular disease or death from any cause. Patients received nucleoside analogues, protease inhibitors, and nonnucleoside reverse-transcriptase inhibitors for a median of 17, 16, and 9 months, respectively. From 1995 to 2001, the rate of admissions for cardiovascular or cerebrovascular disease decreased from 1.7 to 0.9 per 100 patient-years, and the rate of death from any cause decreased from 21.3 to 5.0 deaths per patient-year. No relationship was found between the use of nucleoside analogues, protease inhibitors, or nonnucleoside reverse-transcriptase inhibitors and the hazard of cardiovascular or cerebrovascular events.
Commentary
The use of newer therapies for HIV infection since 1996 has radically changed the management of infected persons, with a dramatic decrease in HIV-associated opportunistic infections and a corresponding increase in survival. However, long-term use of many of the more potent antiretroviral agents has been associated with adverse toxicities, including abnormalities of lipid and insulin metabolism, fat redistribution, diabetes, and hyperlipidemia. Anecdotal reports have attributed premature cardiovascular disease to use of these agents. This study addressed the association between the use of anti-HIV therapy and cardiovascular or cerebrovascular disease.
In this study, no such relationship was found. While the study was relatively large, patients who received potent antiretroviral therapy received it for a relatively short time. Due to the time required for vascular disease to develop, it is conceivable to be unable to discern an effect for several years of use. Primary data from medical records were not examined, and the data were not collected prospectively. Deaths due to causes other than cardiovascular events are often miscoded as cardiovascular, and in spite of best efforts to correct for this, this miscoding may overwhelm any attributable risk to antiretroviral therapy.
The most appropriate method to address these issues would be with a prospective cohort study with the primary data analyzed. Nonetheless, this is an intriguing early evaluation of the risk of vascular disease among persons using potent antiretroviral therapy; it clearly demonstrated, by the decrease in the rate of death from any cause, that HIV-infected persons are much better off since these therapies became available.
Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003; 138: 620-626 .
SUMMARY
This was a prospective observational study at eight private and two public clinics in the United States. Eligible patients were HIV Outpatient Study (HOPS) participants with at least two CD4+ measurements and data on antiretroviral therapy initiation and use for at least 30 days between January 1994 and March 2001. Three CD4+ strata were analyzed: 201 to 350 cells per microliter, 251 to 500 cells per microliter, and 501 to 750 cells per microliter. The mortality rates for persons initiating any antiretroviral therapy or highly active antiretroviral therapy (HAART), defined as the use of three drugs with either a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor or a regimen with two full-dose protease inhibitors, were compared with the rates among persons who deferred receiving antiretroviral therapy.
Data from 1,464 HOPS participants were evaluated; 848 were analyzed in the final model. The mortality rates in the higher CD4+ strata were lower than those in the lower strata. The mortality rates in the lowest (201 to 350 cells per microliter) stratum were significantly lower (P < .001) among persons who initiated antiretroviral therapy than in those persons who deferred receiving antiretroviral therapy. Rates in the upper two strata did not significantly differ between persons who initiated antiretroviral therapy and those who deferred therapy. In addition, persons who initiated antiretroviral therapy in the lower two CD4+ strata were significantly more likely to achieve an HIV viral load below the limits of detection during the follow-up period.
Commentary
The survival benefit of potent antiretroviral therapy for HIV-infected individuals is well established, as are many toxicities associated with therapy. Treating individuals with antiretroviral therapy before they would be at risk for death or developing opportunistic infections would subject these persons to risk without significant benefit.
An accompanying editorial to this manuscript (Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med. 2003; 138:680) describes how the "swing in the pendulum of expert opinion from early, aggressive therapy to a more cautious approach was not concluded from data derived from randomized trials with clinical outcomes." Indeed, some expert treatment guidelines favor delaying the initiation of antiretroviral therapy until CD4+ cell counts decrease to fewer than 200 cells per microliter. The data presented in this article, while not conclusive, suggest that delaying initiation of therapy until this level is reached may be associated with an increased mortality risk.
Factors that may have biased these results include the possible existence of comorbid factors that differentially affected the likelihood of initiation of therapy. In addition, relatively few end points occurred in the CD4+ cell stratum (201 to 350 CD4+ cells per microliter) that formed the basis of the central conclusion (20 deaths among 340 subjects initiating therapy, 13 deaths among 59 patients who delayed therapy). Adjusting for confounding variables in a Cox proportional hazards model found a similar, though nonsignificant, hazard for delaying therapy. These data, while provocative, would require a very large randomized, controlled trial for confirmation. These data should prompt clinicians to carefully evaluate patients who wish to delay the initiation of antiretroviral therapy until CD4+ cell counts are fewer than 200 cells per microliter. 
SUMMARY
This is the report of the phase 3, randomized, open-label study of T-20 versus Optimized Regimen Only (TORO 1) study. Subjects eligible for the study had either evidence of clinical or laboratory resistance to nucleoside and nonnucleoside reverse-transcriptase inhibitors and protease inhibitors and had a plasma human immunodeficiency virus type 1 (HIV-1) RNA of at least 5,000 copies per milliliter at two screening visits. From 48 centers in the United States, Canada, Mexico, and Brazil, 501 patients between December 2000 and June 2001 were randomly placed in a 48-week treatment study of optimized antiretroviral therapy with or without T-20, with an optional 48-week extension. Of the subjects, 491 (326 in the T-20 group, 165 in the control group) used the study medication at least once and had a followup visit to assess safety and HIV-1 RNA level. Virologic failure by predetermined end points allowed changes in therapy and for the control group to receive treatment with T-20.
At 24 weeks, the least-squares mean change in HIV-1 RNA from baseline, using an intent-to-treat analysis, showed a decrease of 1.7 log copies per milliliter in the T-20 group compared with a decrease of 0.8 log copies per milliliter in the control group (P < .001). The mean increases in CD4+ cell counts were 76 cells per microliter and 32 cells per microliter (P < .001) in the two groups, respectively. The only treatment-related side effects that occurred more frequently in the T-20 group were injection site reactions, peripheral neuropathy, and decreased appetite. The addition of T-20 to an optimized antiretroviral regimen appeared to benefit persons who had demonstrable multidrug-resistant HIV-1 infection.
COMMENTARY
Enfuvirtide, or T-20, is the 17th antiretroviral agent approved in the United States for the treatment of HIV infection. Approved in March 2003 for persons who have failed or are intolerant of other antiretroviral agents, it is the first agent in the class of compounds called fusion inhibitors. This peptide with 36 amino acids binds to a region of the HIV-1 envelope gp41 and prevents fusion of the virus with the membrane of the CD4+ cell. T-20 can only be administered parenterally, and its pharmacokinetics requires twice-daily injections. The process to manufacture T-20 is complicated; the manufacturer has initially priced T-20 dosages at approximately $20,000 per year.
With 17 agents available for the treatment of HIV infection, it would be imagined that treatment of the disease would be more simple and straightforward. Unfortunately, due to its ability to rapidly develop resistant mutations integrated into the host genome, infection with HIV-1 has proved difficult to manage. Resistance to and intolerance of all of the available antiretroviral agents have been reported. Isolates resistant to T-20 have already been developed in vitro. Other fusion inhibitors are currently being evaluated in clinical trials. While this will be a useful agent for some antiretroviral-experienced persons with few or no effective drugs available, with good short-term tolerability, its expense and requirement for parenteral administration will limit its widespread use.
Michael A. Polis

Child and Adolescent Health Reviews
Dube SR, Felliti VJ, Dong M, Chapman DP, Giles WH, Anda RF. Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the Adverse Childhood Experiences Study. Pediatrics. 2003;111:564-572.
SUMMARY
The relationship between illicit drug use and adverse childhood experiences (ACEs) was studied by a retrospective survey in a cohort of 8,613 adults who attended a primary care clinic in California. The 10 ACE categories included physical, emotional, or sexual abuse; physical or emotional neglect; growing up with substance abuse, criminality, or mental illness among household member; battered mother or parental separation/divorce. Aspects of illicit drug use included lifetime use, age of initiation, drug use problems, drug addiction, and parenteral drug use.
The study population was predominantly white and educated at the college level, with a mean age of 56 years. There were 26% who reported one ACE, with another 42% reporting two to five or more ACEs. Lifetime illicit drug use (corrected for age) was reported by 27%. These prevalences were similar to those found in other population studies.
For each category of ACE, the likelihood of early drug initiation and of lifetime use was found to increase two-to fourfold over those with no ACE. For individuals with increasing numbers of ACEs, the risks for early initiation of use and for serious drug use problems increased in a graded fashion. Of those who reported five or more ACEs, 9.9% initiated drug use at age 14 years or younger compared to 1.5% of those with one ACE. Similarly, 9.2% of the group with five or more ACEs reported having ever been addicted to drugs compared to 2.1% with one ACE and 0.8% with no ACEs.
Examination of four birth cohorts dating to 1900 for lifetime use of illicit drugs showed the same pattern of graded increase with increasing number of ACE exposures for each cohort, although the absolute number of users was lower for the older population groups. The estimated proportions of each of the three serious forms (drug use problems, drug addiction, parenteral drug use) of illicit drug use attributable to ACEs were 56%, 63%, and 64%, respectively.
COMMENTARY
When Wordsworth wrote, "The child is father of the man," he stated a fundamental truth that has been interpreted differently by scholars and scientists in every era. In the study summarized here, the investigators applied an epidemiologic approach to the challenge of relating childhood experiences to adult behaviors and have succeeded in showing a strong association between a group of adverse experiences and later problems of illicit drug use. This study is the most recently reported of a series carried out as part of the Adverse Childhood Experiences Study, a collaboration between the Kaiser Health Plan's Health Appraisal Center in San Diego, California, and the Centers for Disease Control and Prevention. The study aims to assess the impact of ACEs on a wide variety of health behaviors and outcomes and has shown a strong relationship between the number of ACEs and health and social problems such as smoking, unintended pregnancy, attempted suicide, and others.
The authors rightly stressed the point that, because their findings show that one half to two thirds of serious drug problems are associated with ACEs, efforts to prevent illicit drug use will require much more emphasis on these harmful problems of childhood than they have been given. The authors' recommendation was for pediatricians to become more aware and skillful in identifying problems and supporting families, but a set of problems so pervasive needs more remediation than the work of one professional group can provide. Even child welfare professionals who deal with such issues on a daily basis may be overwhelmed by them. In the context of this study, a call to divert some of the massive resources devoted to the "war on drugs" to the amelioration of family problems instead would be a natural outcome of the findings. In fact, making the prevention of illicit drug use a rationale for devoting more resources to protecting children and preventing family stress might be a successful strategy for child advocates to use with policymakers.
It is troublesome to note that only 32.7% of this study population reported no adverse childhood experiences in spite of the very strict criteria the authors used to classify an experience as adverse. It appears that happy childhoods are not the rule. (For another attempt at defining childhood happiness, see below.) At the same time, even among those who suffered the most ACEs, only small percentages actually reported a serious drug problem. Perhaps the next step in this analysis should be to compare within each ACE group the demographic and other characteristics of those who did and did not use drugs. While the epidemiologic approach cannot supply all the answers to questions about human behavior, it still has more to tell us about this particular set of relationships.
Hillemeier MM, Lynch J, Harper S. Raghunathan T, Kaplan GA. Relative or absolute standards for child poverty: a state-level analysis of infant and child mortality. Am J Public Health. 2003; 93:652-657 .
SUMMARY
Most studies of the relationship of poverty and child health have used the federal poverty line to define poverty. Recently, the concept of "relative deprivation," which is the idea that poverty might better be measured in relation to local rather than national conditions, has gained some currency. There is little information about how that definition of poverty might relate to child health.
To investigate this question, the authors compared the associations of state-referenced and federal poverty measures with states' infant and child mortality rates. State-referenced rates were the percentage of children whose family incomes were less than one half of the median equivalent income in a given state. Federal rates were the percentage of children in the state whose family incomes were below the federal poverty line.
When child mortality rates were plotted against state-referenced child poverty levels state by state, there was a negative correlation that was not statistically significant. When these mortality rates were plotted against federal poverty rates in the states, there was a strong, statistically significant, positive correlation. The same patterns were found for infant mortality. In addition, regression analyses estimating mortality as a function of state median income and of state-referenced child poverty showed that state median income was significantly (P > .0001) and inversely related to child mortality. The authors concluded that "once absolute level of resources is taken into account, variation in relative economic position within states does not appear to be associated with children's mortality risk" (p. 654).
COMMENTARY
This interesting study addressed a complex sociological question: What are the effects of being relatively poorer than your neighbors and others who live in your area compared to the absolute degree of poverty you suffer? For at least one important indicator, the answer is that the absolute degree of poverty is what counts. But, mortality rates are rather crude measures of child health and well-being, and there will undoubtedly be further attempts to answer this question using other measures.
Sociologic questions aside, these results also have some relevance for the ongoing debate about whether it is preferable to strive for uniform national standards, particularly as they relate to public health, or take into account the recognized variations among states. As an example, the disparities in newborn metabolic screening requirements from one state to another and the disagreement about the need to establish a single set of requirements nationally come to mind. The analysis presented here should at least help promote the continuing use of the federal poverty level in the face of calls for "devolution." (This is not to say that concerns about the methodology used to calculate the federal poverty level should not also be addressed and modifications made as appropriate.)
Rogers MAM, Zaragoza-Lao E. Happiness and children's health: an investigation of art, entertainment, and recreation. Am J Public Health. 2003; 93:288-289 .
SUMMARY
Noting the contributions of recreational and amusement activities to children's happiness, the authors set out to determine whether these activities would also contribute to children's health. The study assessed whether the level of art, entertainment, and recreational activities in communities correlated with the health status of children residing there. For each of 20 counties in northwestern Ohio, data from the US economic census was used to determine the basic dollar volume in receipts reported by service establishments in the arts, entertainment, and recreation sector of the economy. These amounts were divided by the county's population size to obtain a mean dollar amount per resident. Health status of children in northwestern Ohio was obtained from analysis of caretaker's ratings of a child's health as excellent, very good, good, fair, or poor in telephone responses to the Ohio Family Health Survey of the Ohio Department of Health.
When children's health status was ranked with mean dollar receipts by ordinal logistic regression, the dollar amounts increased with higher health status, so children who were in excellent health lived in counties with the highest mean receipts, and children with fair or poor health lived in counties with the lowest mean receipts. The correlation between mean receipts and median county income was weakly negative, which suggested that there were probably not more entertainment opportunities in wealthy counties. The conclusion was that communities with more arts, entertainment, and recreation resources are more likely to have healthier children.
COMMENTARY
It is refreshing to come across a study that examines the influence of positive experiences on children's health, and the authors are to be commended for their original approach to the subject. Of course, a statistical analysis of this kind, no matter how carefully done, raises more questions than it answers. What is the relative importance of the recreational sector of a county's economy compared with its other economic sectors as an influence on children's health? What consideration should be given to non-receipt-generating forms of arts and recreation such as parks, playgrounds, and playing fields? If mean receipts represent what county residents are spending on entertainment, do families in counties with more healthy children have more money available to spend on entertainment than those with children in poor health? What are the intervening variables between recreational services and children's health status? The study was not designed to answer these questions. Its greatest value will be to stimulate additional work in this area.
Katherine S. Lobach
